Dr. Ott on the CheckMate-032 Study in Gastric and GEJ Cancer

Patrick Ott, MD, PhD
Published: Thursday, Jul 06, 2017



Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CheckMate-032 study in gastric and gastroesophageal junction (GEJ) cancer.

In this trial, 59 patients with either gastric or GEJ cancer were treated with nivolumab (Opdivo), most of which had received 2 or more prior lines of therapy.

The overall survival was promising, says Ott, with durable responses observed.
 
SELECTED
LANGUAGE


Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CheckMate-032 study in gastric and gastroesophageal junction (GEJ) cancer.

In this trial, 59 patients with either gastric or GEJ cancer were treated with nivolumab (Opdivo), most of which had received 2 or more prior lines of therapy.

The overall survival was promising, says Ott, with durable responses observed.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x